STOCK TITAN

Merus Financials

MRUS
Trailing 12 months to September 30, 2025
Revenue $56.6M +57.5% YoY
Net Income -$381.1M -55.8% YoY
EPS (Diluted) -$5.30 -34.2% YoY
Free Cash Flow -$317.9M -102.2% YoY
Source SEC Filings (10-K/10-Q) Latest period Q3 FY2025, ended Sep 30, 2025 Reported Currency USD FYE December

Merus (MRUS) reported $56.6M in revenue over the twelve months to Sep 30, 2025, up 57.5% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI MRUS FY2024

Development-stage spending is accelerating faster than revenue, widening losses while financing supplies balance-sheet liquidity.

R&D investment rose from $141M in FY2023 to $225M in FY2024 as revenue declined, making development spending the dominant operating commitment. Operating margin deteriorated from -356.2% to -753.0%, indicating that heavier development investment was a major contributor—not scale efficiency—to the widening operating gap.

The financing inflow of $494M more than offset the $186M operating outflow, so 2024 balance-sheet support came from financing rather than internal cash generation. Reported liquidity equaled 46.8 months of the latest annual operating outflow, alongside a 6.5x current ratio, describing substantial short-term coverage despite continued losses.

Cash conversion closely tracked accounting losses: free cash flow was -$188M versus operating cash flow of -$186M in FY2024, so the cash cost was primarily operational rather than fixed-asset investment. Shares outstanding rose from 57.8M to 68.8M, linking the financing-led support to shareholder dilution.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Cash Runway Dilution R&DIntensity Revenue Progress BurnTrend BalanceSheet 58 / 100
Financial Health Score 58/100
Scored as: Emerging companies peer group

Scored against emerging companies for FY2024. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Merus's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway
64
Dilution
29
R&D Intensity
93
Revenue Progress
38
Burn Trend
32
Balance Sheet
92
Altman Z-Score Safe
28.21

Merus scores 28.21, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($6.8B) relative to total liabilities ($134.8M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
3/7

Merus passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality No Cash Backing
N/A

Merus reported a net loss of $215.3M while operations used $185.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$36.1M
YoY-17.8%
5Y CAGR+3.0%

Merus generated $36.1M in revenue in fiscal year 2024. This represents a decrease of 17.8% from the prior year.

EBITDA
-$269.6M
YoY-74.8%

Merus's EBITDA was -$269.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 74.8% from the prior year.

Net Income
-$215.3M
YoY-39.0%

Merus reported -$215.3M in net income in fiscal year 2024. This represents a decrease of 39.0% from the prior year.

EPS (Diluted)
-$3.35
YoY-11.7%

Merus earned -$3.35 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 11.7% from the prior year.

Cash & Balance Sheet

Free Cash Flow
-$187.5M
YoY-28.3%

Merus recorded an outflow of $187.5M in free cash flow in fiscal year 2024, representing a cash shortfall after capex. This represents a decrease of 28.3% from the prior year.

Cash & Debt
$293.3M
YoY+43.6%
5Y CAGR+8.2%

Merus held $293.3M in cash as of fiscal year 2024; long-term debt is not reported for that period.

Shares Outstanding
69M
YoY+19.4%
5Y CAGR+19.0%

Merus had 69M shares outstanding in fiscal year 2024. This represents an increase of 19.4% from the prior year.

Dividends Per Share

Not reported for fiscal year 2024.

Margins & Returns

Return on Equity
-33.2%
YoY+10.3pp
5Y CAGR+8.8pp

Merus's ROE was -33.2% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is up 10.3 percentage points from the prior year.

Gross Margin

Not reported for fiscal year 2024.

Operating Margin

Not shown for fiscal year 2024: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for fiscal year 2024: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending
$225.4M
YoY+60.2%
5Y CAGR+32.3%

Merus invested $225.4M in research and development in fiscal year 2024. This represents an increase of 60.2% from the prior year.

Capital Expenditures
$1.7M
YoY-58.1%
5Y CAGR-5.6%

Merus invested $1.7M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 58.1% from the prior year.

Share Buybacks

Not reported for fiscal year 2024.

MRUS Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

MRUS quarterly income statement
MetricQ3'25Q2'25Q1'25Q4'24Q3'24Q2'24Q1'24Q4'23
Revenue$12.2M+37.6%$8.8M-66.7%$26.5M+189.8%$9.1M-22.4%$11.8M+60.6%$7.3M-7.1%$7.9M-11.7%$8.9M
R&D Expenses$80.0M-14.8%$93.9M+17.2%$80.1M+7.6%$74.4M+17.7%$63.2M+28.7%$49.1M+27.3%$38.6M-5.2%$40.7M
SG&A Expenses$28.6M+13.3%$25.3M+14.2%$22.1M-5.4%$23.4M+12.5%$20.8M-8.1%$22.6M+40.2%$16.1M+2.0%$15.8M
Operating Income-$96.5M+12.6%-$110.3M-45.7%-$75.7M+14.6%-$88.7M-22.7%-$72.2M-12.2%-$64.4M-37.5%-$46.8M+1.5%-$47.5M
Income Tax$5.8M+210.8%$1.9M+0.9%$1.9M+5.5%$1.8M-40.9%$3.0M+28.5%$2.3M+111.0%$1.1M+5.9%$1.0M
Net Income-$95.5M+39.6%-$158.2M-64.0%-$96.5M-212.0%-$30.9M+69.0%-$99.9M-99.6%-$50.0M-45.2%-$34.5M+42.7%-$60.2M
EPS (Diluted)-$1.26+43.5%-$2.23-59.3%-$1.40-241.5%-$0.41+71.9%-$1.46-80.2%-$0.81-37.3%-$0.59+45.9%-$1.09

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.

MRUS Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

MRUS quarterly balance sheet
MetricQ3'25Q2'25Q1'25Q4'24Q3'24Q2'24Q1'24Q4'23
Total Assets$904.2M-7.8%$980.2M+34.1%$730.9M-6.6%$782.7M-7.3%$844.7M-5.3%$892.2M+79.1%$498.1M+9.4%$455.5M
Current Assets$691.9M-9.9%$768.3M+47.1%$522.3M-8.2%$569.1M-14.6%$666.3M-17.4%$806.6M+96.6%$410.3M+11.2%$368.8M
Cash & Equivalents$367.5M-17.0%$442.8M+124.5%$197.2M-32.8%$293.3M-32.3%$433.0M-31.2%$629.5M+253.3%$178.2M-12.8%$204.2M
Accounts Receivable$19.2M+13.6%$16.9M+18.9%$14.2M+1026.3%$1.3M+11.2%$1.1M-38.4%$1.8M-96.9%$58.7M+2317.7%$2.4M
Total Liabilities$129.3M-6.6%$138.4M+2.7%$134.8M0.0%$134.8M-4.7%$141.4M-2.8%$145.5M-2.1%$148.6M+49.9%$99.2M
Current Liabilities$86.8M-5.2%$91.6M+2.7%$89.1M+2.4%$87.1M+8.7%$80.1M-1.0%$80.9M+3.0%$78.5M+13.6%$69.1M
Total Equity$774.9M-7.9%$841.7M+41.2%$596.1M-8.0%$647.9M-7.9%$703.3M-5.8%$746.8M+113.7%$349.4M-1.9%$356.3M
Retained Earnings-$1.3B-7.8%-$1.2B-14.9%-$1.1B-10.0%-$968.4M-3.3%-$937.5M-11.9%-$837.6M-6.4%-$787.5M-4.6%-$753.1M

Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.

MRUS Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

MRUS quarterly cash flow statement
MetricQ3'25Q2'25Q1'25Q4'24Q3'24Q2'24Q1'24Q4'23
Operating Cash Flow-$84.9M-22.7%-$69.2M+28.2%-$96.5M-44.7%-$66.7M+17.1%-$80.4M-1527.7%$5.6M+112.7%-$44.4M-22.1%-$36.3M
Capital Expenditures$328K+272.7%$88K-48.5%$171K+755.0%$20K-81.5%$108K-92.7%$1.5M+2242.9%$63K+142.3%-$26K
Free Cash Flow-$85.2M-23.0%-$69.3M+28.3%-$96.6M-44.9%-$66.7M+17.2%-$80.5M-2037.2%$4.2M+109.4%-$44.5M-22.2%-$36.4M
Investing Cash Flow$329K+104.4%-$7.5M+14.4%-$8.7M+88.8%-$77.7M+41.9%-$133.7M-4235.9%$3.2M+126.8%-$12.1M-470.6%-$2.1M
Financing Cash Flow$6.1M-98.2%$333.3M+4842.6%$6.7M-16.4%$8.1M-25.9%$10.9M-97.6%$444.9M+1375.3%$30.2M+1910.4%$1.5M

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

MRUS Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

MRUS quarterly financial ratios
MetricQ3'25Q2'25Q1'25Q4'24Q3'24Q2'24Q1'24Q4'23
Operating Margin-794.1%-1250.0%-285.9%-969.9%-613.6%-878.0%-593.4%-531.9%
Net Margin-786.2%-1792.2%-364.2%-338.3%-848.7%-682.5%-436.8%-672.9%
Return on Equity-12.3%+6.5pp-18.8%-2.6pp-16.2%-11.4pp-4.8%+9.4pp-14.2%-7.5pp-6.7%+3.2pp-9.9%+7.0pp-16.9%
Return on Assets-10.6%+5.6pp-16.1%-2.9pp-13.2%-9.3pp-4.0%+7.9pp-11.8%-6.2pp-5.6%+1.3pp-6.9%+6.3pp-13.2%
Current Ratio7.97-0.4x8.39+2.5x5.86-0.7x6.54-1.8x8.32-1.7x9.97+4.7x5.23-0.1x5.34
Debt-to-Equity0.170.0x0.16-0.1x0.230.0x0.210.0x0.200.0x0.19-0.2x0.43+0.1x0.28
FCF Margin-701.6%-785.2%-364.8%-729.5%-684.1%56.7%-563.5%-406.9%

Not reported in any period shown, so not listed: Gross Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Frequently Asked Questions

What is Merus's annual revenue?

Merus (MRUS) reported $36.1M in total revenue for fiscal year 2024. This represents a -17.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Merus's revenue growing?

Merus (MRUS) revenue declined by 17.8% year-over-year, from $43.9M to $36.1M in fiscal year 2024.

Is Merus profitable?

No, Merus (MRUS) reported a net income of -$215.3M in fiscal year 2024.

Merus (MRUS) reported diluted earnings per share of -$3.35 for fiscal year 2024. This represents a -11.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Merus (MRUS) had EBITDA of -$269.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

Merus (MRUS) has a return on equity of -33.2% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

Merus (MRUS) recorded an outflow of $187.5M in free cash flow during fiscal year 2024. This represents a -28.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Merus (MRUS) recorded an outflow of $185.8M in operating cash flow during fiscal year 2024, representing cash used by core business activities.

Merus (MRUS) had $782.7M in total assets as of fiscal year 2024, including both current and long-term assets.

Merus (MRUS) invested $1.7M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

Merus (MRUS) invested $225.4M in research and development during fiscal year 2024.

Merus (MRUS) had 69M shares outstanding as of fiscal year 2024.

Merus (MRUS) had a current ratio of 6.54 as of fiscal year 2024, which is generally considered healthy.

Merus (MRUS) had a debt-to-equity ratio of 0.21 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

Merus (MRUS) had a return on assets of -27.5% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

At the end of fiscal year 2024, Merus (MRUS) held $724.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $185.8M over that year. Dividing the one by the other, the reported balance equals about 47 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Merus (MRUS) has an Altman Z-Score of 28.21, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Merus (MRUS) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Merus (MRUS) reported a net loss of $215.3M while operations used $185.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Merus (MRUS) scores 58 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top